» Articles » PMID: 31020900

Atorvastatin Has a Dose-Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Double-Blind Randomized Controlled Trials

Overview
Date 2019 Apr 26
PMID 31020900
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background Kidney function decreases during the lifetime, and this decline is a powerful predictor of both kidney and cardiovascular outcomes. Statins lower cardiovascular risk, which may relate to beneficial effects on kidney function. We studied whether atorvastatin influences kidney function decline and assessed the association between individual kidney function slopes and cardiovascular outcome. Methods and Results Data were collected from 6 large atorvastatin cardiovascular outcome trials conducted in patients not selected for having kidney disease. Slopes of serum creatinine reciprocals representing measures of kidney function change ([mg/dL]/y), were analyzed in 30 621 patients. Based on treatment arms, patients were categorized into 3 groups: placebo (n=10 057), atorvastatin 10 mg daily (n=12 763), and 80 mg daily (n=7801). To assess slopes, mixed-model analyses were performed for each treatment separately, including time in years and adjustment for study. These slopes displayed linear improvement over time in all 3 groups. Slope estimates for patients randomized to placebo or atorvastatin 10 mg and 80 mg were 0.009 (0.0008), 0.011 (0.0006), and 0.014 (0.0006) (mg/dL)/y, respectively. A head-to-head comparison of atorvastatin 10 and 80 mg based on data from 1 study ( TNT [Treating to New Targets]; n=10 001) showed a statistically significant difference in slope between the 2 doses ( P=0.0009). From a Cox proportional hazards model using slope as a predictor, a significant ( P<0.0001) negative association between kidney function and cardiovascular outcomes was found. Conclusions In patients at risk of or with cardiovascular disease, atorvastatin improved kidney function over time in a dose-dependent manner. In the 3 treatment groups, kidney function improvement was strongly associated with lower cardiovascular risk. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifiers: NCT00327418; NCT00147602; NCT00327691.

Citing Articles

2024 Guidelines of the Taiwan Society of Cardiology on the Primary Prevention of Atherosclerotic Cardiovascular Disease --- Part I.

Chao T, Lin T, Cheng C, Wu Y, Ueng K, Wu Y Acta Cardiol Sin. 2024; 40(5):479-543.

PMID: 39308649 PMC: 11413940. DOI: 10.6515/ACS.202409_40(5).20240724A.


Different doses of atorvastatin in the treatment of patients with cardiorenal syndrome Type-2: A retrospective cohort study.

Zhang E, Xu T, Zhang B, Meng L Pak J Med Sci. 2024; 40(4):568-571.

PMID: 38545029 PMC: 10963987. DOI: 10.12669/pjms.40.4.8706.


Genetic variations in HMGCR and PCSK9 and kidney function: a Mendelian randomization study.

Park S, Kim S, Lee S, Kim Y, Cho S, Kim K Kidney Res Clin Pract. 2023; 42(4):460-472.

PMID: 37448291 PMC: 10407636. DOI: 10.23876/j.krcp.22.237.


The Link between Magnesium Supplements and Statin Medication in Dyslipidemic Patients.

Nartea R, Mitoiu B, Ghiorghiu I Curr Issues Mol Biol. 2023; 45(4):3146-3167.

PMID: 37185729 PMC: 10136538. DOI: 10.3390/cimb45040205.


Antidyslipidemia Pharmacotherapy in Chronic Kidney Disease: A Systematic Review and Bayesian Network Meta-Analysis.

Liao G, Wang X, Li Y, Chen X, Huang K, Bai L Pharmaceutics. 2023; 15(1).

PMID: 36678635 PMC: 9862001. DOI: 10.3390/pharmaceutics15010006.


References
1.
Koren M, Hunninghake D . Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. J Am Coll Cardiol. 2004; 44(9):1772-9. DOI: 10.1016/j.jacc.2004.07.053. View

2.
Deedwania P, Stone P, Merz C, Cosin-Aguilar J, Koylan N, Luo D . Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation. 2007; 115(6):700-7. DOI: 10.1161/CIRCULATIONAHA.106.654756. View

3.
Go A, Chertow G, Fan D, McCulloch C, Hsu C . Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351(13):1296-305. DOI: 10.1056/NEJMoa041031. View

4.
Fassett R, Robertson I, Ball M, Geraghty D, Cardinal J, Coombes J . Effects of atorvastatin on NGAL and cystatin C in chronic kidney disease: a post hoc analysis of the LORD trial. Nephrol Dial Transplant. 2011; 27(1):182-9. DOI: 10.1093/ndt/gfr193. View

5.
Pedersen T, Faergeman O, Kastelein J, Olsson A, Tikkanen M, Holme I . High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005; 294(19):2437-45. DOI: 10.1001/jama.294.19.2437. View